Aura Biosciences, Inc. (AURA)

6,90 -0,25 (-3,50%) Al cierre: 01:00PM EDT

Aura Biosciences, Inc.

80 Guest Street
5th Floor
Boston, MA 02135
United States
617 500 8864
https://www.aurabiosciences.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 88

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Elisabet de los Pinos Ph.D.	Founder, CEO, President & Director	895,16k	N/A	1974
Ms. Julie B. Feder	Chief Financial Officer	604,2k	N/A	1971
Dr. Mark Plavsic D.V.M., Ph.D.	Chief Technology Officer	N/A	N/A	1961
Mr. Conor Kilroy	General Counsel & Secretary	N/A	N/A	1982
Mr. Patrick Nealon	Senior Vice President of Clinical Development Operations	N/A	N/A	N/A
Dr. Bruce Brown M.D.	Senior VP & Therapeutic Area Head of Urologic Oncology	N/A	N/A	N/A
Dr. Anthony Daniels M.D.	Therapeutic Area Head of Ocular Oncology	N/A	N/A	N/A
Dr. Richard Mountfield Ph.D.	Senior Vice President of Regulatory Affairs & Quality	N/A	N/A	N/A
Dr. Jill J. Hopkins M.D.	Chief Medical Officer & President of Research and Development	N/A	N/A	1965

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmette–guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Aura Biosciences, Inc., a día 1 de julio de 2024, es 7. Las puntuaciones base son Auditoría: 7; Tablero: 6; Derechos de los accionistas: 8; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.